Quark Pharmaceuticals Inc.

Quark Pharmaceuticals Inc. is a biopharmaceutical company specializing in RNA interference technology to develop innovative therapeutics for serious diseases such as cancer and neurological disorders. Founded in 1993 and headquartered in Fremont, US, Quark Pharmaceuticals focuses on RNAi-based therapeutic solutions. The company has experienced significant advancements in its strategy and operations.

Quark has secured funding through various rounds, including the latest Series I round in October 2011, raising USD 57. 00 mn from GoAhead Ventures, bringing the total amount raised to USD 57. 00 mn and a current valuation of USD 95. 13 mn.

The CEO is Dan Cafaro. Quark Pharmaceuticals, Inc. specializes in developing RNAi-based therapeutics for critical diseases, including QPI-1002 for renal protection and QPI-1007 for neurological disorders. Their innovative products are used in clinical settings by healthcare professionals and research institutions across North America, Europe, and select Asian markets.

In the most recent year, 2010, Quark Pharmaceuticals reported revenue of USD 5. 20 mn and an EBITDA of USD -20. 84 mn. The company generates income through partnerships and collaborations, engaging in joint ventures and licensing agreements to mitigate the financial risks of drug development while earning milestone payments and royalties from successful product sales.

Quark Pharmaceuticals aims to expand its product line and market presence. The company is focused on launching new RNA-based therapeutics while exploring entry into emerging markets in Asia and Europe by 2023. The recent Series I funding of USD 57. 00 mn will support these initiatives, facilitating research and development efforts to enhance its therapeutic offerings.